These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12374902)

  • 1. Inotropic agents and immune modulation.
    Sasayama S
    Cardiovasc Drugs Ther; 2002 May; 16(3):237-43. PubMed ID: 12374902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inotropic agents].
    Sasayama S
    Nihon Rinsho; 2003 May; 61(5):807-14. PubMed ID: 12755007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Kubo SH
    Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
    [No Abstract]   [Full Text] [Related]  

  • 5. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic agents in the treatment of heart failure: despair or hope?
    Sasayama S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):703-9. PubMed ID: 9110113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ; Verdouw PD
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract]   [Full Text] [Related]  

  • 8. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
    Holubarsch C
    Cardiology; 1997; 88 Suppl 2():12-20. PubMed ID: 9142431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phosphodiesterase inhibition as a new positive-inotropic principle].
    Hartmann A; Saeed M; Sütsch G; Bing RJ
    Dtsch Med Wochenschr; 1986 Dec; 111(51-52):1971-7. PubMed ID: 3539571
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inotropic agents in advanced and refractory heart failure].
    Mangiavacchi M; Gronda E
    Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
    von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
    Tauke J; Han D; Gheorghiade M
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):761-8. PubMed ID: 7873474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 14. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
    Colucci WS; Wright RF; Braunwald E
    N Engl J Med; 1986 Feb; 314(6):349-58. PubMed ID: 2418353
    [No Abstract]   [Full Text] [Related]  

  • 15. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 16. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
    Endoh M
    Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New positive inotropic agents in the treatment of left ventricular dysfunction.
    De Luca L; Proietti P; Palombaro GL; Battagliese A; Celotto A; Bucciarelli Ducci C; Fedele F
    Ital Heart J; 2004 Jun; 5 Suppl 6():63S-67S. PubMed ID: 15185917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesnarinone: a new inotropic agent for treating congestive heart failure.
    Cavusoglu E; Frishman WH; Klapholz M
    J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
    Hasenfuss G; Pieske B; Castell M; Kretschmann B; Maier LS; Just H
    Circulation; 1998 Nov; 98(20):2141-7. PubMed ID: 9815868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.